Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Purchased by Boothbay Fund Management LLC

Boothbay Fund Management LLC boosted its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 7.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 650,023 shares of the company's stock after acquiring an additional 44,067 shares during the period. Boothbay Fund Management LLC owned approximately 1.31% of Mineralys Therapeutics worth $8,002,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Franklin Resources Inc. boosted its stake in shares of Mineralys Therapeutics by 17.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,745,513 shares of the company's stock worth $21,138,000 after buying an additional 262,922 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Mineralys Therapeutics by 5.0% in the fourth quarter. Vanguard Group Inc. now owns 1,432,042 shares of the company's stock valued at $17,628,000 after purchasing an additional 68,811 shares during the last quarter. Jennison Associates LLC increased its position in Mineralys Therapeutics by 55.4% during the 4th quarter. Jennison Associates LLC now owns 1,082,006 shares of the company's stock worth $13,319,000 after buying an additional 385,726 shares during the period. ADAR1 Capital Management LLC boosted its holdings in Mineralys Therapeutics by 15.4% in the 4th quarter. ADAR1 Capital Management LLC now owns 841,541 shares of the company's stock valued at $10,359,000 after purchasing an additional 112,140 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Mineralys Therapeutics by 6.6% in the third quarter. Geode Capital Management LLC now owns 620,853 shares of the company's stock valued at $7,520,000 after buying an additional 38,527 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Stock Up 1.9 %

MLYS traded up $0.27 during trading hours on Wednesday, hitting $14.21. The stock had a trading volume of 996,104 shares, compared to its average volume of 727,281. The company's fifty day simple moving average is $13.09 and its 200 day simple moving average is $12.36. Mineralys Therapeutics, Inc. has a 1 year low of $13.15 and a 1 year high of $14.47. The stock has a market cap of $921.89 million, a PE ratio of -3.90 and a beta of -0.39.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.02. As a group, equities analysts expect that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Wall Street Analysts Forecast Growth

MLYS has been the topic of several research analyst reports. The Goldman Sachs Group reduced their price objective on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Guggenheim reaffirmed a "buy" rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. Finally, HC Wainwright increased their price objective on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the stock a "buy" rating in a research report on Wednesday, April 2nd.

Insider Activity

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the company's stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.06, for a total transaction of $129,729.42. Following the sale, the chief financial officer now directly owns 215,340 shares in the company, valued at $2,597,000.40. This represents a 4.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider David Malcom Rodman sold 55,771 shares of the business's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $15.76, for a total transaction of $878,950.96. Following the completion of the sale, the insider now directly owns 116,704 shares of the company's stock, valued at approximately $1,839,255.04. This trade represents a 32.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 93,213 shares of company stock worth $1,360,567. Insiders own 33.24% of the company's stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.